NasdaqCM:ENGNBiotechs
enGene Holdings (ENGN) Valuation in Focus Following Promising Phase 2 Bladder Cancer Trial Results
enGene Holdings (ENGN) is drawing attention after announcing positive preliminary results from the pivotal cohort of its Phase 2 LEGEND trial. The data showed a high complete response rate and a favorable safety profile in challenging bladder cancer cases.
See our latest analysis for enGene Holdings.
enGene Holdings’ impressive momentum really kicked in after its recent LEGEND trial data sent the stock soaring, highlighted by a 40% seven-day share price return and a staggering 129% gain over...